Related Experiment Video
Updated: Jul 22, 2026
07:56
A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices
Published on: August 11, 2021
Platelet monoamine oxidase in schizophrenia: a meta-analysis
1Departamento de Psiquiatria, Faculdade de Medicina, Universidade de São Paulo, Brazil.
Schizophrenia Research
|September 1, 1992
Summary
Schizophrenia patients on neuroleptics show lower platelet monoamine oxidase (MAO) levels. However, drug-free schizophrenia patients exhibit MAO levels comparable to controls, suggesting medication influences these findings.
Area of Science:
- Neuroscience
- Psychiatry
- Biochemistry
Background:
- Platelet monoamine oxidase (MAO) is an enzyme implicated in neurotransmitter metabolism.
- Altered MAO activity has been investigated as a potential biomarker in schizophrenia.
- Previous studies have yielded conflicting results regarding MAO levels in schizophrenia.
Purpose of the Study:
- To systematically evaluate platelet monoamine oxidase (MAO) levels in individuals with schizophrenia.
- To investigate the influence of neuroleptic medication on platelet MAO activity in schizophrenia patients.
Main Methods:
- A comprehensive meta-analysis was conducted on all available publications concerning platelet MAO in schizophrenia.
- Studies included were in English and other languages.
- Data from medicated and drug-free schizophrenia patients were compared to control groups.
Main Results:
- Most studies indicated significantly lower platelet MAO levels in medicated schizophrenia patients compared to controls.
- Neuroleptic administration was associated with a reduction in MAO levels.
- Platelet MAO levels in drug-free schizophrenia patients were generally similar to those of controls.
Conclusions:
- Neuroleptic medication appears to significantly lower platelet monoamine oxidase (MAO) levels in schizophrenia.
- Platelet MAO levels in drug-free schizophrenia patients do not consistently differ from controls.
- The findings highlight the critical role of medication status in interpreting MAO levels in schizophrenia research.
Related Concept Videos
01:27Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
01:29Biological Causes of Schizophrenia
Schizophrenia, a severe psychiatric disorder, arises from a complex interplay of biological factors, including genetic predisposition, structural brain abnormalities, neurotransmitter dysregulation, and developmental irregularities. These factors collectively contribute to the onset and progression of the disorder, which typically manifests in late adolescence or early adulthood.
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin studies.
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin studies.